Other Ear, Nose, Mouth and Throat Diagnoses DRG Reimbursement

DRG 156 groups admissions for miscellaneous ear, nose, mouth and throat diagnoses without a Major Complication or Comorbidity or a Complication or Comorbidity; it captures lower-severity otolaryngologic inpatient care. This grouping matters for inpatient reimbursement because it generally yields lower Medicare payment rates and depends on precise coding to ensure correct Diagnosis-Related Group assignment.

DRG 156 Overview

DRG 156 covers hospital admissions for other ear, nose, mouth and throat diagnoses that do not involve a Major Complication or Comorbidity or a Complication or Comorbidity. Typical cases include non-complex otolaryngologic conditions managed with medical therapy or straightforward procedures. This Diagnosis-Related Group is significant for Medicare payment because it represents lower-severity inpatient encounters with correspondingly lower reimbursement relative to higher-severity groups. Accurate coding of diagnoses and procedures directly influences assignment to this Diagnosis-Related Group and associated Medicare inpatient payment.

Acute procedural efficacy and safety studies focused on otolaryngologic interventions for non-complex ENT diagnoses: These trials evaluate short-term outcomes of common hospital-based procedures such as incision and drainage of peritonsillar abscesses, flexible endoscopy-guided foreign body removal from the upper airway, or inpatient management protocols for complicated otitis media without CC/MCC. They enroll adults and children admitted for acute ENT problems requiring procedural intervention and measure metrics like procedure success, immediate complication rates, length of stay, and need for escalation of care. Findings are relevant to providers and payers because they inform best-practice procedural pathways that can reduce variability in care, avoid unnecessary ICU use, and shorten inpatient stays for DRG 156 patients.
Comparative effectiveness and care pathway trials comparing conservative versus escalation strategies for common ENT diagnoses: These studies compare inpatient treatment approaches—for example, early surgical intervention versus optimized medical therapy for severe tonsillitis or inpatient observation protocols for epistaxis—to determine which strategies yield better symptom control, lower readmission rates, and more efficient resource use. They typically enroll heterogeneous adult and pediatric cohorts with ENT conditions that lack major comorbidity (aligning with DRG 156) and assess outcomes such as treatment failure, need for secondary procedures, patient-reported symptom resolution, and total hospital costs. Results guide clinicians and payers in selecting pathways that balance clinical benefit with cost-effectiveness, supporting protocolization that can reduce unnecessary procedures and admissions.
Post-discharge outcomes and readmission risk prediction studies for patients hospitalized with non-CC/MCC ENT diagnoses: These observational and prospective cohort studies track functional recovery, complication rates (eg, recurrent infection, persistent obstruction), health-related quality of life, and 30–90 day readmission or ED revisit rates after discharge for patients treated for ENT conditions within DRG 156. They focus on identifying risk factors—such as age, social determinants, or index treatment modality—that predict poor recovery or early return to care, and may evaluate transitional care interventions like targeted discharge education or early outpatient follow-up. This research is important to providers and payers because reducing preventable readmissions and optimizing post-discharge care can improve patient outcomes while lowering downstream costs associated with repeat inpatient utilization.

Acute procedural efficacy and safety studies focused on otolaryngologic interventions for non-complex ENT diagnoses: These trials evaluate short-term outcomes of common hospital-based procedures such as incision and drainage of peritonsillar abscesses, flexible endoscopy-guided foreign body removal from the upper airway, or inpatient management protocols for complicated otitis media without CC/MCC. They enroll adults and children admitted for acute ENT problems requiring procedural intervention and measure metrics like procedure success, immediate complication rates, length of stay, and need for escalation of care. Findings are relevant to providers and payers because they inform best-practice procedural pathways that can reduce variability in care, avoid unnecessary ICU use, and shorten inpatient stays for DRG 156 patients.
Comparative effectiveness and care pathway trials comparing conservative versus escalation strategies for common ENT diagnoses: These studies compare inpatient treatment approaches—for example, early surgical intervention versus optimized medical therapy for severe tonsillitis or inpatient observation protocols for epistaxis—to determine which strategies yield better symptom control, lower readmission rates, and more efficient resource use. They typically enroll heterogeneous adult and pediatric cohorts with ENT conditions that lack major comorbidity (aligning with DRG 156) and assess outcomes such as treatment failure, need for secondary procedures, patient-reported symptom resolution, and total hospital costs. Results guide clinicians and payers in selecting pathways that balance clinical benefit with cost-effectiveness, supporting protocolization that can reduce unnecessary procedures and admissions.
Post-discharge outcomes and readmission risk prediction studies for patients hospitalized with non-CC/MCC ENT diagnoses: These observational and prospective cohort studies track functional recovery, complication rates (eg, recurrent infection, persistent obstruction), health-related quality of life, and 30–90 day readmission or ED revisit rates after discharge for patients treated for ENT conditions within DRG 156. They focus on identifying risk factors—such as age, social determinants, or index treatment modality—that predict poor recovery or early return to care, and may evaluate transitional care interventions like targeted discharge education or early outpatient follow-up. This research is important to providers and payers because reducing preventable readmissions and optimizing post-discharge care can improve patient outcomes while lowering downstream costs associated with repeat inpatient utilization.

OpenPayer

Summary & Overview

Other Ear, Nose, Mouth and Throat Diagnoses without CC/MCC: Inpatient Reimbursement Overview

DRG 156 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes